stockrow
Friday 6 November 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023.
- Revenue
- +256.1%
- EPS
- +120.0%
- Free cash flow
- +146.5%
Quarter to June 2026, against a year earlier
1.00
0.02
−1.96%
Follow HOWL
Alert me
Werewolf Therapeutics, Inc. (HOWL) P/E ratio
Werewolf Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| IMA ImageneBio, Inc. compare | n/m |
| TIL Instil Bio, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)